

Rewrite page 10, penultimate paragraph, as:

*Ex*

Val-Ala-Leu-Asn-Ser-Pro-Leu-Ser-Gly-Gly-Met-Arg-Gly-Ile-Arg-Gly-Ala-Asp-  
Phe-Gln-Xxx-Phe-Gln-Gln-Ala-Arg-Ala-Val-Gly-Leu-Ala-Gly-Thr-Phe-Arg-  
Ala-Phe-Leu-Ser-Ser-Arg-Leu-Gln-Asp-Leu-Tyr-Ser-Ile-Val-Arg-Arg-Ala-Asp-  
Arg-Ala-Ala-Val-Pro-Ile-Val (SEQ ID NO: 2).

IN THE CLAIMS

Cancel claims 43-62, without prejudice or disclaimer, and add claims as follows.

64. An isolated peptide consisting of

- Ex*
- a) the amino acid sequence Val-Ala-Leu-Asn-Ser-Pro-Leu-Ser-Gly-Gly-Met-Arg-Gly-Ile-Arg-Gly-Ala-Asp-Phe-Gln-Cys-Phe-Gln-Gln-Ala-Arg-Ala-Val-Gly-Leu-Ala-Gly-Thr-Phe-Arg-Ala-Phe-Leu-Ser-Ser-Arg-Leu-Gln-Asp-Leu-Tyr-Ser-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro-Ile-Val-Asn-Leu-Lys-Asp-Glu-Leu-Leu-Phe-Pro-Ser-Trp-Glu-Ala-Leu-Phe-Ser-Gly-Ser-Glu-Gly-Pro-Leu-Lys-Pro-Gly-Ala-Arg-Ile-Phe-Ser-Phe-Asp-Gly-Lys-Asp-Val-Leu-Arg-His-Pro-Thr-Trp-Pro-Gln-Lys-Ser-Val-Trp-His-Gly-Ser-Asp-Pro-Asn-Gly-Arg-Arg-Leu-Thr-Glu-Ser-Tyr-Cys-Glu-Thr-Trp-Arg-Thr-Glu-Ala-Pro-Ser-Ala-Thr-Gly-Gln-Ala-Ser-Ser-Leu-Leu-Gly-Gly-Arg-Leu-Leu-Gly-Gln-Ser-Ala-Ala-Ser-Cys-His-His-Ala-Tyr-Ile-Val-Leu-Cys-Ile-Glu-Asn-Ser-Phe-Met-Thr-Ala-Ser (HF-COLL-18/514cf) (SEQ ID NO: 1) or
- b) an amidated, acetylated, phosphorylated, or glycosylated derivative of the isolated peptide.

65. The isolated peptide of claim 64 consisting of the amino acid sequence Val-Ala-Leu-Asn-Ser-Pro-Leu-Ser-Gly-Gly-Met-Arg-Gly-Ile-Arg-Gly-Ala-Asp-Phe-Gln-Cys-Phe-Gln-Gln-Ala-Arg-Ala-Val-Gly-Leu-Ala-Gly-Thr-Phe-Arg-Ala-Phe-Leu-Ser-Ser-Arg-Leu-Gln-Asp-Leu-Tyr-Ser-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro-Ile-Val-Asn-Leu-Lys-Asp-Glu-Leu-Leu-Phe-Pro-Ser-Trp-Glu-Ala-Leu-Phe-Ser-Gly-Ser-Glu-Gly-Pro-Leu-Lys-Pro-Gly-Ala-Arg-Ile-Phe-Ser-Phe-Asp-Gly-Lys-Asp-Val-Leu-Arg-His-Pro-Thr-Trp-Pro-Gln-Lys-Ser-Val-Trp-His-Gly-Ser-Asp-Pro-Asn-Gly-Arg-Arg-Leu-Thr-Glu-Ser-Tyr-Cys-Glu-Thr-Trp-Arg-Thr-Glu-Ala-Pro-Ser-Ala-Thr-Gly-Gln-Ala-Ser-Ser-Leu-Leu-Gly-Gly-Arg-Leu-Leu-Gly-Gln-Ser-Ala-Ala-Ser-Cys-His-His-Ala-Tyr-Ile-Val-Leu-Cys-Ile-Glu-Asn-Ser-Phe-Met-Thr-Ala-Ser (HF-COLL-18/514cf) (SEQ ID NO: 1).
66. The isolated peptide of claim 64 consisting of the amidated, acetylated, phosphorylated, or glycosylated derivative of the isolated peptide .
67. A process for the preparation of the isolated peptide according to claim 64 through prokaryotic or eukaryotic expression.
68. A process for the preparation of the isolated peptide according to claim 64 through isolation from human blood using chromatographic methods.

69. A process for the preparation of the isolated peptide according to claim 64 by solid-phase and liquid-phase synthesis and purification by chromatographical methods.
70. A medicament containing the isolated peptide according to claim 64 as the active ingredient in combination with excipients.
- ε3 71. The medicament according to claim 70 in a form for oral administration.
72. The medicament according to claim 70 in a form for parenteral, intravenous, or intramuscular administration.
73. The medicament according to claim 70 in a form for intracutaneous or intrathecal administration.
74. The medicament according to claim 70 in a form for intranasal administration.
75. The medicament according to claim 70 in a form for or local-topical application.
76. The medicament according to claim 70 in an aerosol form for transpulmonary application.